Complete Story
07/15/2026
Recent Oncology Related FDA Approvals and Expanded Indications
FDA approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance
FDA approves Gilead's Trodelvy® in combination with Merck's KEYTRUDA® or KEYTRUDA QLEX™ for treatment of Advanced Triple-Negative Breast Cancer in adults
FDA approves AstraZeneca's Truqap combination as targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
FDA approves AstraZeneca's Datroway TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
More Info
Report Broken Links
Have you encountered a problem with a URL (link) on this page not working or displaying an error message? Help us fix it!
